E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.
about
E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
E2F signature is predictive fo ...... to cytotoxic-based treatments.
@en
E2F signature is predictive fo ...... to cytotoxic-based treatments.
@nl
type
label
E2F signature is predictive fo ...... to cytotoxic-based treatments.
@en
E2F signature is predictive fo ...... to cytotoxic-based treatments.
@nl
prefLabel
E2F signature is predictive fo ...... to cytotoxic-based treatments.
@en
E2F signature is predictive fo ...... to cytotoxic-based treatments.
@nl
P2093
P2860
P50
P1433
P1476
E2F signature is predictive fo ...... to cytotoxic-based treatments
@en
P2093
Juan Iovanna
Martin Bigonnet
Odile Gayet
Patricia Santofimia-Castaño
P2860
P356
10.1038/S41598-018-26613-Z
P407
P577
2018-05-29T00:00:00Z